4Szczepiorkowski ZM, Bandarenko N, Kim HC, et al. Guidelines on the use of therapeutic apheresis in clinical practice: evidence based approach from the Apheersis Applications Committee of the American Society for Apheresis [J]. J Clin Apher,2007,22(3) :106-175. 被引量：1
5Dervenoulas J, Tsirigotis P, Bollas G, et al. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS): treatment outcome, relapses, prognostic factors. A single-center experience of 48 cases [J]. Ann Hematol, 2000,79 (2) : 66-72. 被引量：1
6Shamseddine A, Saliba T, Aoun E, et al. Thrombotic thrombocytopenic purpura: 24 years of experience at the American University of Beirut Medical Center [J]. J Clin Apher 2004,19(3) : 119-124. 被引量：1
7Bandarenko N, Brecher ME. United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange [J]. J Clin Apher 1998,13(3) : 133-141. 被引量：1
8Altuntas F, Aydogdu I, Kabukcu S, et al. Therapeutic plasma exchange for the treatment of thrombotic thrombocytopenie purpura: a retrospective muhieenter study [J]. Transfus Apher Sei, 2007,36 ( 1 ) : 57-67. 被引量：1
9Kieseier BC, Hartung HP. Therapeutic strategies in the Guillain-Barre syndrome [J]. Semin Neurol,2003,23 (2):159-168. 被引量：1
10Dilley A, Gregson NA, Hadden RD, et al. Effects on axonal conduction of anti-ganglioside sera and sera from patients with Guillain-Barre syndrome[J].J Neuroimmunol, 2003,139(1-2) :133-140. 被引量：1
